Multicenter Phase II, Open-Label Trial of Intratumoral Tavokinogene Telseplasmid (TAVO, pIL-12) Plus Electroporation in Combination with Intravenous Pembrolizumab in Patients With Stage III/IV Melanoma Who Are Progressing on Either Pembrolizumab or Nivolumab Treatment
Evaluate the efficacy of the combination of KEYTRUDA®, a registered trademark of Merck Sharp & Dohme Corp., and TAVO in advanced metastatic melanoma patients that are progressing on pembrolizumab or nivolumab.
Open-label, Phase II, Multicenter Study of Enhancing Pembrolizumab Responses in Melanoma through Intratumoral pIL-12 Electroporation
Assess the anti-tumor efficacy (defined as the best overall response rate using RECIST v1.1) and safety of the combination of plasmid interleukin-12 electroporation and pembrolizumab in patients with low tumor-infiltrating lymphocyte (TIL) melanoma†.
†This is a collaboration with University of California, San Francisco
OMS-140 Evaluation of Pharmacodynamic Effects of Intratumoral Delivery of Plasmid IL-12 Electroporation in Patients with Triple Negative Breast Cancer (TNBC)
Evaluate the potential of intratumoral treatment with pIL-12 delivered via electroporation to promote a pro-inflammatory molecular and histological signature in patients with triple negative breast cancer.
OMS-131 This phase II trial studies how well tavokinogene telseplasmid with electroporation, pembrolizumab, and epacadostat work in treating patients with squamous cell carcinoma of the head and neck that cannot be removed by surgery.
Determine whether the combination of tavokinogene telseplasmid (tavo)-electroporation (EP), pembrolizumab, and epacadostat increases the best overall response rate (BORR) in squamous cell carcinoma of the head and neck (SCCHN) compared with historical data for pembrolizumab monotherapy.